Classification ![]() |
|
Compound class | Antibody |
International Nonproprietary Names ![]() |
|
INN number | INN |
9365 | urelumab |
Synonyms ![]() |
BMS 663513 | BMS-663513 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 373 |
Other databases | |
GtoPdb PubChem SID | 318164830 |
Search PubMed clinical trials | urelumab |
Search PubMed titles | urelumab |
Search PubMed titles/abstracts | urelumab |
Comments |
Urelumab (BMS-663513) is an investigational monoclonal antibody with agonist activity at the tumour necrosis factor (TNF) receptor, 4-1BB (TNFRSF9), being investigated for potential clinical immunostimulatory activity in the immuno-oncology setting [2-4]. Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequences for urelumab are identical matches for peptides claimed in patent WO2005035584, which leads to identification of clone 20H4-9-IgG4 [1]. |